<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253617</url>
  </required_header>
  <id_info>
    <org_study_id>AXCAN-PHOCCC04-01</org_study_id>
    <secondary_id>UCLA-0501033-01</secondary_id>
    <secondary_id>CDR0000449701</secondary_id>
    <nct_id>NCT00253617</nct_id>
  </id_info>
  <brief_title>Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery</brief_title>
  <official_title>Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy&#xD;
      uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain&#xD;
      kind of light. When the drug is active, tumor cells are killed. This may be an effective&#xD;
      treatment for cholangiocarcinoma. It is not yet known whether stent placement and&#xD;
      photodynamic therapy using porfimer sodium are more effective than stent placement alone in&#xD;
      treating cholangiocarcinoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying stent placement and photodynamic therapy&#xD;
      using porfimer sodium to see how well they work compared to stent placement alone as&#xD;
      palliative treatment in treating patients with stage III or stage IV cholangiocarcinoma that&#xD;
      cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the overall survival time in patients with unresectable Bismuth type III or IV,&#xD;
           stage III-IV cholangiocarcinoma treated with double plastic endoprostheses insertion&#xD;
           with vs without adjuvant photodynamic therapy using porfimer sodium as palliative&#xD;
           treatment.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the effect of these regimens on cholestasis in these patients.&#xD;
&#xD;
        -  Compare the 1-year survival rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare health-related quality of life of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are&#xD;
      stratified according to participating center.&#xD;
&#xD;
      Patients undergo endoscopic or percutaneous drainage followed by insertion of bilateral&#xD;
      plastic endoprostheses into the bile ducts. Patients are then randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive porfimer sodium IV on day 1. Patients undergo endoscopic laser&#xD;
           light therapy to the tumor site on day 3.&#xD;
&#xD;
        -  Arm II: Patients receive no further treatment. Quality of life is assessed at baseline&#xD;
           and then at weeks 2, 13, 26, 39, 52, and 65.&#xD;
&#xD;
      After completion of study treatment, patients are followed within 30-90 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Cholangiocarcinoma of the Extrahepatic Bile Duct</condition>
  <condition>Cholangiocarcinoma of the Gallbladder</condition>
  <condition>Unresectable Extrahepatic Bile Duct Cancer</condition>
  <condition>Unresectable Gallbladder Cancer</condition>
  <condition>Recurrent Extrahepatic Bile Duct Cancer</condition>
  <condition>Recurrent Gallbladder Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laser therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>phototherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed cholangiocarcinoma&#xD;
&#xD;
          -  Stage III or IV disease&#xD;
&#xD;
          -  Bismuth type III or IV disease&#xD;
&#xD;
          -  Tumor mass or stricture on cholangiogram and CT scan&#xD;
&#xD;
          -  Unresectable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 30-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 2,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Hematocrit ≥ 27%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  PT or INR ≤ 2 times upper limit of normal (correctable with vitamin K)&#xD;
&#xD;
          -  No decompensated cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known porphyria or hypersensitivity to porphyrin&#xD;
&#xD;
          -  No clinically significant acute or chronic medial or psychological illness that would&#xD;
             preclude study treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             basal cell skin cancer&#xD;
&#xD;
          -  No concurrent untreated primary diagnosis of anxiety or depression&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 13 weeks since prior and no concurrent chemotherapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 13 weeks since prior and no concurrent brachytherapy or radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior metal stent insertion&#xD;
&#xD;
          -  No prior surgical resection of cholangiocarcinoma&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior photodynamic therapy for this disease&#xD;
&#xD;
          -  More than 60 days since prior investigational drugs&#xD;
&#xD;
          -  No concurrent administration of the following:&#xD;
&#xD;
          -  Ursodiol&#xD;
&#xD;
          -  Herbal products that may increase bile flow, including any of the following:&#xD;
&#xD;
          -  Andrographis paniculata&#xD;
&#xD;
          -  Chelidonium majus L&#xD;
&#xD;
          -  Curcumin L&#xD;
&#xD;
          -  Cynara scolymus L (artichoke)&#xD;
&#xD;
          -  Gentiana lutea&#xD;
&#xD;
          -  Mentha x piperita (peppermint)&#xD;
&#xD;
          -  Peumus boldus Mol&#xD;
&#xD;
          -  Taraxacum officinale (dandelion)&#xD;
&#xD;
          -  No administration of any of the following within 7 days of porfimer sodium injection:&#xD;
&#xD;
          -  Supplements in vitamins C, E, and β-carotene&#xD;
&#xD;
          -  Camellia sinensis (green tea)&#xD;
&#xD;
          -  Silymarin&#xD;
&#xD;
          -  EGb761&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Farrell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axcan Pharma, Incorporated</name>
      <address>
        <city>Mont-Saint-Hilaire</city>
        <state>Quebec</state>
        <zip>J3H 6C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

